Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

31.50 -0.75 (-2.33%)

Streaming Delayed Price Updated: 1:00 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Analyst Expectations For Genmab's Future ↗

September 24, 2025

Via Benzinga

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

September 03, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) Meets Peter Lynch's GARP Investment Criteria ↗

September 03, 2025

Discover GMAB, a biotech stock matching Peter Lynch's GARP strategy. It offers strong earnings growth, a low PEG ratio, and excellent financial health for long-term investors.

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB): A High-Value Biotech Play with Strong Fundamentals ↗

September 01, 2025

Genmab (GMAB) is a high-value biotech stock with a low P/E ratio, strong financial health, and robust profitability, making it a standout undervalued opportunity.

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB): An Affordable Growth Candidate in Biotechnology ↗

August 28, 2025

Discover GENMAB A/S (GMAB), an affordable growth stock with strong revenue expansion, solid profitability, and a reasonable valuation in the biotech sector.

Via Chartmill

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

August 26, 2025

From Genmab A/S

Via Business Wire

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% ↗

August 08, 2025

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat.

Via Benzinga

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

August 07, 2025

From Genmab

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Biotech Stock With Strong Growth and Reasonable Valuation ↗

July 01, 2025

GENMAB A/S (NASDAQ:GMAB) is a biotech stock with strong earnings growth, high profitability, and a reasonable valuation, making it a candidate for long-term investors following Peter Lynch's strategy.

Via Chartmill

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

June 15, 2025

From Genmab

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Candidate for GARP Investors ↗

June 09, 2025

GENMAB A/S (NASDAQ:GMAB) offers strong earnings growth, high profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy.

Via Chartmill

Why Genmab Stock Smashed It on Monday ↗

June 02, 2025

Via The Motley Fool

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

June 02, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Growth Stock Showing Technical Breakout Potential ↗

May 24, 2025

GENMAB A/S (NASDAQ:GMAB) is a strong growth stock with solid fundamentals and a promising technical breakout pattern, offering potential for investors seeking growth opportunities.

Via Chartmill

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for Affordable Growth Investors ↗

May 21, 2025

GENMAB A/S (NASDAQ:GMAB) offers strong growth, solid profitability, and attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for GARP Investors ↗

May 15, 2025

GENMAB A/S (NASDAQ:GMAB) offers strong growth, profitability, and a reasonable valuation, making it a standout pick for GARP investors following Peter Lynch’s strategy.

Via Chartmill

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

May 14, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals. ↗

May 06, 2025

GENMAB A/S -SP ADR is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:GMAB showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

May 01, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock ↗

May 01, 2025

GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB): a strong growth stock preparing for the next leg up?. ↗

April 29, 2025

Based on a technical and fundamental analysis of NASDAQ:GMAB we can say: GENMAB A/S -SP ADR (NASDAQ:GMAB), a strong growth stock, setting up for a breakout.

Via Chartmill

Why Peter Lynch may take an interest in GENMAB A/S -SP ADR (NASDAQ:GMAB) ↗

April 23, 2025

Peter Lynch, one of the most successful investors of all time, focused on growth stocks with strong fundamentals and a business model that’s easy to understand. Let’s analyze whether GENMAB A/S -SP ADR...

Via Chartmill

Despite its growth, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains within the realm of affordability. ↗

April 19, 2025

GENMAB A/S -SP ADR was identified as a growth stock that isn't overvalued. NASDAQ:GMAB is excelling in various growth indicators while maintaining a solid financial footing.

Via Chartmill

Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish ↗

April 15, 2025

Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize...

Via Stocktwits

Topics Stocks

What Analysts Are Saying About Genmab Stock ↗

April 09, 2025

Via Benzinga

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

March 31, 2025

From Genmab A/S

Via Business Wire

Does GENMAB A/S -SP ADR (NASDAQ:GMAB) match Peter Lynch’s “Invest in What You Know” philosophy? ↗

March 28, 2025

Peter Lynch was known for finding hidden gems in the market before they became mainstream. Is GENMAB A/S -SP ADR (NASDAQ:GMAB) one of those under-the-radar stocks that fits his legendary strategy?

Via Chartmill

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer ↗

March 27, 2025

Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.

Via Benzinga

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

March 27, 2025

From Genmab A/S

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.